For which non-muscle invasive bladder cancer is Re-Transurethral Resection more valuable? Which bladder cancer deserves Re-TUR?
dc.authorwosid | akgül, murat/AGE-2468-2022 | |
dc.contributor.author | Akgül, Murat | |
dc.contributor.author | Doğan, Çağrı | |
dc.contributor.author | Yazıcı, Cenk Murat | |
dc.contributor.author | Şahin, Mehmet Fatih | |
dc.contributor.author | İşal Arslan, Ayşegül | |
dc.contributor.author | Öznur, Meltem | |
dc.date.accessioned | 2022-05-11T14:02:49Z | |
dc.date.available | 2022-05-11T14:02:49Z | |
dc.date.issued | 2021 | |
dc.department | Fakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı | |
dc.department | Fakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Tıbbi Patoloji Ana Bilim Dalı | |
dc.description.abstract | Aim: In this study, we aimed to evaluate the re-transurethral resection (re-TUR) pathologies and to compare the pathology results between transurethral resection of the bladder (TUR-B) and re-TUR for non-muscle invasive bladder cancer (NMIBC). Additionally, we aimed to assess the factors affecting the re-TUR pathology and try to define more valuable re-TUR patient groups. We also aimed to evaluate the effect of re-TUR on recurrence and progression. Material and Method: We performed re-TUR in intermediate/high-risk NMIBC patients, 4-6 weeks after the index TUR-B. Both TUR-B and re-TUR pathology characteristics, including tumor stage, grade, size, number, lymphovascular invasion (LVI), carcinoma in situ (CIS), variant pathology, and intermediate/high-risk status were analyzed retrospectively. The recurrence and progression rates were also evaluated according to re-TUR. Results: A total of 78 patients with NMIBC were included in the study. The index TUR-B pathologies were Ta-Low: 6 (7,7%), Ta-High: 5 (6,4%), T1-Low: 14 (17,9%), T1-High: 53 (67,9%). Re-TUR positivity was n: 40 (51 %), and upstaging/upgrading at re-TUR was n: 11 (14 %) in all groups. Re-TUR positivity was significantly higher in high-risk compared to intermediate-risk NMIBC (p:0,026). Re-TUR positivity was higher in patients with hydronephrosis, C15. LVI, differentiation, size (>3 cm), and multiple tumor presence (p<0,05). There was no significant relationship between recurrence/progression and re-TUR (p>0,05). Discussion: Residual tumor was common after the index TUR-B, and upstaging after re-TUR was very important Re-TUR is critically important in high-risk NMIBC, presence of hydronephrosis, CIS, LVI, variant pathology, size (>3 cm). and multiple number of tumors. | |
dc.identifier.doi | 10.4328/ACAM.20722 | |
dc.identifier.endpage | 1262 | |
dc.identifier.issn | 2667-663X | |
dc.identifier.issue | 11 | en_US |
dc.identifier.startpage | 1258 | |
dc.identifier.uri | https://doi.org/10.4328/ACAM.20722 | |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/4500 | |
dc.identifier.volume | 12 | |
dc.identifier.wos | WOS:000732422900013 | |
dc.identifier.wosquality | N/A | |
dc.indekslendigikaynak | Web of Science | |
dc.institutionauthor | Akgül, Murat | |
dc.institutionauthor | Doğan, Çağrı | |
dc.institutionauthor | Yazıcı, Cenk Murat | |
dc.institutionauthor | Şahin, Mehmet Fatih | |
dc.institutionauthor | İşal Arslan, Ayşegül | |
dc.institutionauthor | Öznur, Meltem | |
dc.language.iso | en | |
dc.publisher | Bayrakol Medical Publisher | |
dc.relation.ispartof | Annals Of Clinical And Analytical Medicine | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Bladder Cancer | |
dc.subject | TUR-B | |
dc.subject | Re-TUR | |
dc.subject | Pathology | |
dc.subject | Progression | |
dc.subject | Recurrence | |
dc.subject | Impact | |
dc.title | For which non-muscle invasive bladder cancer is Re-Transurethral Resection more valuable? Which bladder cancer deserves Re-TUR? | |
dc.type | Article |
Dosyalar
Orijinal paket
1 - 1 / 1
Yükleniyor...
- İsim:
- 4500.pdf
- Boyut:
- 181.53 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin / Full Text